Immunological effects of chemotherapy in spontaneous breast cancers

Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response

(2013) Lára Hannesdóttir et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells

(2013) Yuting Ma et al.   IMMUNITY

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

(2013) Laurence Zitvogel et al.   IMMUNITY

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

(2013) Sherene Loi et al.   JOURNAL OF CLINICAL ONCOLOGY

Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy

(2013) Paula D. Bos et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Current trends of anticancer immunochemotherapy

(2013) Erika Vacchelli et al.   OncoImmunology

Novel multifunctional antibody approved for the treatment of breast cancer

(2013) Domenico Mavilio et al.   OncoImmunology

Trial watch

(2013) Erika Vacchelli et al.   OncoImmunology

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

(2013) Sherene Loi   OncoImmunology

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer

(2012) Q. Wang et al.   CANCER RESEARCH

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

(2012) Metamia Ciampricotti et al.   NATURE MEDICINE

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

An Immunosurveillance Mechanism Controls Cancer Cell Ploidy

(2012) L. Senovilla et al.   SCIENCE

Trial Watch: Monoclonal antibodies in cancer therapy

(2012) Lorenzo Galluzzi et al.   OncoImmunology

Trial watch

(2012) Laura Senovilla et al.   OncoImmunology

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

(2011) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

(2011) M. Michaud et al.   SCIENCE

Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy

(2011) David G. DeNardo et al.   Cancer Discovery

The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity

(2010) SaeGwang Park et al.   CANCER CELL

Development of metastatic HER2+ breast cancer is independent of the adaptive immune system

(2010) Metamia Ciampricotti et al.   JOURNAL OF PATHOLOGY

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

(2010) Massimo Ammirante et al.   NATURE

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

(2009) Carsten Denkert et al.   JOURNAL OF CLINICAL ONCOLOGY

The anticancer immune response: indispensable for therapeutic success?

(2008) Laurence Zitvogel et al.   JOURNAL OF CLINICAL INVESTIGATION